An ionic contrast agent inhibits platelet-dependent thrombin generation and boosts the effect of abciximab.
Al Dieri
R
R
de Muinck
E
E
Hemker
H C
HC
Béguin
S
S
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000187:drug effects / Q000494:pharmacology*; D000925:Anticoagulants / Q000494:pharmacology; D001792:Blood Platelets / Q000378:metabolism; D003287:Contrast Media / Q000494:pharmacology*; D004357:Drug Synergism; D006490:Hemostatics / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000187:drug effects / Q000494:pharmacology*; D007477:Ions; D007485:Ioxaglic Acid / Q000494:pharmacology; D013917:Thrombin / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000187:drug effects
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D003287:Contrast Media; D006490:Hemostatics; D007140:Immunoglobulin Fab Fragments; D007477:Ions; D013917:Thrombin; D000077284:Abciximab; D007485:Ioxaglic Acid